Literature DB >> 33011919

A non-compensatory analysis of quality of life in breast cancer survivors using multivariate hidden Markov modeling.

Edward H Ip1,2, Beverly J Levine3, Nancy E Avis3.   

Abstract

PURPOSE: Health-related quality of life (HRQoL) is a multidimensional concept comprising multiple domains such as physical, emotional, and social well-being. Many analyses use a sum score to represent the construct. However, this approach implies that gain in one domain can compensate for a deficit in another, and thus such analyses may not capture HRQoL profiles. Additionally, within-individual change over time, such as improvement in one domain but deterioration in another, may not be detected. The objectives of this research are to demonstrate the utility of a non-compensatory approach by (1) evaluating this approach applied to HRQoL data, and (2) comparing the approach to a compensatory method.
METHODS: Data from a sample of 653 breast cancer survivors (BCS) provided five measurement time points over 18 months. We analyzed the scores from five domains on the FACT-B questionnaire (physical, functional, social, and emotional well-being and breast cancer-related concerns) using the multivariate hidden Markov model (MHMM), a non-compensatory approach that identifies different HRQoL states and associated BCS subgroups and their trajectories.
RESULTS: The MHMM delineated six states. States 1 and 2 had low well-being scores across all domains, with state 2 slightly better than state 1. States 3 and 4 had similar overall HRQoL scores, but different profiles with compensation occurring across the domains of both physical and social well-being. States 5 and 6 had almost identical overall scores with compensation occurring between the domains of both social and emotional well-being. Over time, states 3-6 mostly "communicated" with each other (with moderate probabilities of transitioning between states). Compensation across domains could mask subtle changes occurring in BCS. We found that a trend analysis using both compensatory and non-compensatory approaches showed improvement in the HRQoL in BCS over time.
CONCLUSION: The non-compensatory analysis of FACT-B shows differential profiles and trajectories in the HRQoL of BCS not captured by the sum score or one-domain-at-a-time approach.

Entities:  

Keywords:  Emotional well-being; FACT-B; Masking due to compensation; Social well-being; Sum score; Transition analysis

Mesh:

Year:  2020        PMID: 33011919      PMCID: PMC7887059          DOI: 10.1007/s11136-020-02648-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  17 in total

1.  The case for domains of function in quality of life assessment.

Authors:  Michelle J Naughton; Sally A Shumaker
Journal:  Qual Life Res       Date:  2003       Impact factor: 4.147

2.  Health-related quality of life during adjuvant radiotherapy in breast cancer.

Authors:  Sinikka Luutonen; Harri Sintonen; Teija Stormi; Eeva Salminen
Journal:  Qual Life Res       Date:  2013-11-08       Impact factor: 4.147

3.  Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.

Authors:  Hideki Murasawa; Takayuki Sugiyama; Yuki Matsuoka; Takashi Okabe; Amiko Hino; Nobumichi Tanaka; Mikio Sugimoto; Masafumi Oyama; Kiyohide Fujimoto; Shigeo Horie; Shinichi Noto; Kojiro Shimozuma
Journal:  Qual Life Res       Date:  2019-04-25       Impact factor: 4.147

4.  Comparison of subgroups of breast cancer patients on pain and co-occurring symptoms following chemotherapy.

Authors:  Dale J Langford; Steven M Paul; Bruce Cooper; Kord M Kober; Judy Mastick; Michelle Melisko; Jon D Levine; Fay Wright; Marilyn J Hammer; Frances Cartwright; Kathryn A Lee; Bradley E Aouizerat; Christine Miaskowski
Journal:  Support Care Cancer       Date:  2015-07-04       Impact factor: 3.603

5.  Latent Class Analysis Reveals Distinct Subgroups of Patients Based on Symptom Occurrence and Demographic and Clinical Characteristics.

Authors:  Christine Miaskowski; Laura Dunn; Christine Ritchie; Steven M Paul; Bruce Cooper; Bradley E Aouizerat; Kimberly Alexander; Helen Skerman; Patsy Yates
Journal:  J Pain Symptom Manage       Date:  2015-01-31       Impact factor: 3.612

6.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

7.  Quality of life and survival: the role of multidimensional symptom assessment.

Authors:  V T Chang; H T Thaler; T A Polyak; A B Kornblith; J M Lepore; R K Portenoy
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

Review 8.  Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors.

Authors:  Joan R Bloom; Dana M Petersen; Soo H Kang
Journal:  Psychooncology       Date:  2007-08       Impact factor: 3.894

9.  Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach.

Authors:  Clement K Gwede; Brent J Small; Pamela N Munster; Michael A Andrykowski; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2007-11-28       Impact factor: 3.603

10.  The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes.

Authors:  Dorit Pud; Sarah Ben Ami; Bruce A Cooper; Bradley E Aouizerat; Dorit Cohen; Ruth Radiano; Pnina Naveh; Rivka Nikkhou-Abeles; Vered Hagbi; Orly Kachta; Aliza Yaffe; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2007-12-21       Impact factor: 3.612

View more
  1 in total

1.  The Impact of Surgical Treatment with Adjuvant Chemotherapy for Ovarian Cancer on Disorders in the Urinary System and Quality of Life in Women.

Authors:  Marcin Opławski; Beniamin Oskar Grabarek; Agata Średnicka; Justyna Czarniecka; Agata Panfil; Zbigniew Kojs; Dariusz Boroń
Journal:  J Clin Med       Date:  2022-02-27       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.